100751-62-0

Basic information

• Product Name: 6-BroMo-2-(tert-butyldiMethylsilyloxyMethyl)naphthalene
• Synonyms: 6-BroMo-2-(tert-butyldiMethylsilyloxyMethyl)naphthalene;(6-Bromonaphthalen-2-ylmethoxy)(tert-butyl)dimethylsilane
• CAS NO: 100751-62-0
• Molecular Formula: C17H23BrOSi
• Molecular Weight: 351.35342
• Product Categories: Aromatics, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 100751-62-0.mol

Chemical Properties

• Appearance: /
• Solubility: Chloroform, DCM, DMF, DMSO, Ethyl Acetate
• CAS DataBase Reference: 6-BroMo-2-(tert-butyldiMethylsilyloxyMethyl)naphthalene(CAS DataBase Reference)
• NIST Chemistry Reference: 6-BroMo-2-(tert-butyldiMethylsilyloxyMethyl)naphthalene(100751-62-0)
• EPA Substance Registry System: 6-BroMo-2-(tert-butyldiMethylsilyloxyMethyl)naphthalene(100751-62-0)

Safety Data

• Hazardous Substances Data: 100751-62-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-2-(tert-butyldimethylsilyloxymethyl)naphthalene is used as an intermediate in the synthesis of 2-Naphthylcarbapenem derivatives, which are broad-spectrum antibiotics. These derivatives exhibit enhanced potency against methicillin-resistant Staphylococcus aureus (MRSA), a significant concern in the medical field due to its resistance to many common antibiotics.
The compound's unique structure allows for the development of new antibiotics that can effectively combat drug-resistant bacterial strains, making it a crucial component in the fight against antibiotic resistance. Its use in the pharmaceutical industry is focused on improving the efficacy of existing treatments and developing novel therapeutic options for various bacterial infections.

Upstream product

• 5773-80-8 6-bromo-2-naphthoic acid 
• 33626-98-1 methyl 6-bromo-2-naphthoate 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 100751-63-1 (6-bromo-2-naphthy)methanol 

Relevant articles and documents

Design, synthesis and biological evaluation of GPR55 agonists

GPR55, a G protein-coupled receptor, is an attractive target to alleviate inflammatory and neuropathic pain and treat osteoporosis and cancer. Identifying a potent and selective ligand will aid to further establish the specific physiological roles and pharmacology of the receptor. Towards this goal, a targeted library of 22 compounds was synthesized in a modular fashion to obtain structure-activity relationship information. The general route consisted of coupling a variety of p-aminophenyl sulfonamides to isothiocyanates to form acylthioureas. For the synthesis of a known naphthyl ethyl alcohol motif, route modification led to a shorter and more efficient process. The 22 analogues were analyzed for their ability to serve as agonists at GPR55 and valuable information for both ends of the molecule was ascertained.

(PIPERIDIN-3-YL)(NAPHTHALEN-2-YL)METHANONE DERIVATIVES AND RELATED COMPOUNDS AS INHIBITORS OF THE HISTONE DEMETHYLASE KDM2B FOR THE TREATMENT OF CANCER

The present invention relates to (piperidin-3-yl)(naphthalen-2-yl) methanone derivatives and related compounds as inhibitors of one or more histone demethylses, such as KDM2b. The invention also provides pharmaceutically acceptable compositions comprising

NOVEL MCH RECEPTOR ANTAGONISTS

The present invention relates to a melanin concentrating hormone antagonist compound of formula I: or a pharmaceutically acceptable salt thereof, useful for the treamtment useful fog treating Type H diabetes and/or obesity.